These interactions, which influence targets associated with the cancer immune response, suggest that BJIKT enhances T cell function and TNF signaling and suppresses TGF-β signaling, leading to cell cycle arrest, apoptosis, and amplification of pembrolizumab’s anticancer effects. This evidence concerns the gene TGFB1 and cancer.